Home Nav
Nextech Invest Logo

Paul Workman

Alfred Scheidegger

Paul Workman PhD DSc (Hon) FRS FMedSci FSB FRSC is the Chief Executive and President of The Institute of Cancer Research (ICR) in London UK. He is also Harrap Professor of Pharmacology and Therapeutics and Director of the Cancer Research UK (CRUK) Centre at the ICR and Royal Marsden. From 1997 to 2016 Dr Workman was Head of the ICR’s Division of Cancer Therapeutics and Director of the CRUK Cancer Therapeutics Unit – the world’s largest academic cancer drug discovery centre. He has been elected a Fellow of the Royal Society, Fellow of the Academy of Medical Sciences, Fellow of the Royal Society of Medicine, Fellow of the Society of Biology, Fellow of the Royal Society of Chemistry and Fellow of the European Academy of Cancer Sciences and he is CRUK Life Fellow. He was formerly Biology Section Head of Cancer Research, AstraZeneca Ltd. Dr Workman was also the scientific founder of two oncology companies and has served as a consultant to many others. He has won a number of awards for his discovery and development of new cancer drugs. He is a Cancer Research UK Life Fellow and winner of the 2010 Royal Society of Chemistry George and Christine Sosnovsky Award for Cancer Therapy and the 2012 Royal Society of Chemistry World Entrepreneur of the Year Award.

 

59th ASH Annual Meeting

09.12. – 12.12.2017

Atlanta, USA

  • 13.11.2017

    Jounce Therapeutics reports third quarter 2017 financial...

  • 13.11.2017

    Tracon Pharmaceuticals announces positive results from...

  • 10.11.2017

    Blueprint Medicines announces new data from ongoing...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close